Related Experiment Videos
Erythrocyte 2,3-diphosphoglycerate in liver diseases
T Nakano1, H Fujioka, S Tamura
1Third Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
The American Journal of Gastroenterology
|December 1, 1987
Summary
Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) levels increase with liver disease severity. Even without hypoxia, 2,3-DPG is higher in liver cirrhosis and hepatocellular carcinoma than in chronic obstructive pulmonary disease.
Area of Science:
- Biochemistry
- Pathophysiology
- Hematology
Background:
- Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) is crucial for oxygen transport.
- Liver diseases and chronic obstructive pulmonary disease (COPD) can affect oxygen homeostasis.
Purpose of the Study:
- To investigate erythrocyte 2,3-DPG levels in patients with liver diseases and COPD.
- To correlate 2,3-DPG levels with disease severity and biochemical markers.
Main Methods:
- Measurement of erythrocyte 2,3-DPG concentrations.
- Assessment of serum albumin, total bile acids, and arterial blood pH.
- Comparison between patient groups (liver disease, COPD) and normal subjects.
Main Results:
- 2,3-DPG levels increased with liver disease severity: chronic persistent hepatitis < chronic active hepatitis < liver cirrhosis < cirrhosis with hepatocellular carcinoma.
- A negative correlation was observed between 2,3-DPG and serum albumin in liver diseases.
- 2,3-DPG levels were higher in hepatocellular carcinoma/liver cirrhosis than in hypoxic COPD, even in nonhypoxic liver disease patients.
Conclusions:
- Erythrocyte 2,3-DPG levels rise with increasing liver disease severity.
- Elevated 2,3-DPG in liver cirrhosis and hepatocellular carcinoma is not solely due to hypoxia and exceeds levels seen in COPD.